Growth That Doesn't Convince: TICMPL's Cost Trap and the Street's Exit
TI delivered 33% revenue growth and 39% profit expansion, but margin compression from commodity headwinds and TICMPL volumes running 20–30% below management's own comfort level are stretching credibility. The street is voting with its feet — FII ownership down, stock down 54% from its all-time high.
₹7,330 Cr
+33% YoY
₹421 Cr
+39% YoY
5.7%
Down from prior year; commodity drag
311 units
Analyst: 'should be higher'
TI's headline numbers tell a boom story—33% revenue growth, 39% profit expansion—but the quarter's honest read is messier. Consolidated PAT of ₹421 Cr masks a margin squeeze that management is banking on commodity normalization to heal. Meanwhile, the company's high-stakes EV venture, TICMPL, is running 20–30% behind volumes that management itself admits should be higher, and costs are 75% above the baseline needed for profitability. The market has already judged: stock down 54% from its all-time high of ₹4,810.8, FII ownership down 3.97pp over five quarters, and analysts branding it a 'Hold' at best.
What held up on the call
Double-digit growth trajectory at consolidated level
SupportedDelivered 32.7% YoY revenue, 39.2% PAT
Medical business growing 20% YoY with profitability scaling
SupportedConfirmed on call; exact Q2 contribution not separated
Cost headwinds will be recovered in 1–2 quarters
OverstatedQ2 OPM 10.0% vs. prior guidance; timeline unproven
TICMPL volumes scaling across four businesses
ContradictedTruck 311, 3W 2,242, SCV 483, Tractor 50 units; analyst: 'not happy with any numbers'
TICMPL HCV will be EBITDA breakeven Q4 FY27
UnverifiedTarget stated; not yet achieved; costs 75% above run-rate
The margin squeeze
Here's the real story of Q2: commodity surge, cell price spikes, and rupee weakness hit the business harder and faster than the company's pricing power could recover. Engineering and Metal Formed Products divisions both saw PBIT margins compress despite volume growth. The response? Management is betting on a 1–2 quarter lag to pass through cost increases to OEMs and customers. That timing is explicitly unproven—management itself said 'the market may not be ready' for price hikes. The alternative levers they cited (BOM optimization, deal realization improvements) are incremental, not game-changing.
TICMPL: the capital trap
TICMPL is TI's ₹600–700 Cr annual capex sink, a push into electric trucks, 3-wheelers, SCVs, and tractors with grand ambitions (₹1 Bn revenue by 2030). The problem: execution is lagging and external validation is gone. The PE partner who wrote the original ₹2,250 Cr cheque has not invested any further capital after the initial stake. TI is now funding the venture entirely on its own cash, and the volumes tell you why external investors are skeptical. Q2 TICMPL volumes: Truck 311 units, 3W 2,242 units, SCV 483 units, Tractor 50 units. These are sub-scale for a business burning ₹250 Cr+ per quarter in capex. Analyst Vipulkumar Shah was blunt during Q&A: 'I am not happy with any of the four numbers. All four numbers should be higher.' Management acknowledged the miss but offered no revised targets—instead retreating to 'market share matters, we have 25–26% in two segments.'
I am not happy with any of the four numbers. In my view, all four numbers should be higher.
Breakeven is promised for Q4 FY27—three quarters away—but costs are running ₹75 Cr above baseline, and management's confidence hinges on price increases ('one to two quarters to settle prices with customers and OEMs') that the market 'may not be ready' to absorb. This is not a credible path to profitability; it's a hope.
What changed on this call
Cost pressure timeline extended 1–2 quarters (vs. immediate recovery prior call implied); no change to FY27 guidance
TICMPL capex Q3 reaffirmed at ₹250 Cr; total group capex Rs 600–700 Cr FY27 unchanged
EV breakeven timeline reaffirmed: HCV Q4 FY27, two others Q4 FY28; no slip
Medical business 20% growth and double-digit teen profitability target post-Q3 reaffirmed
Analyst pushback on TICMPL volumes (Shah, Desai, Gnanasundaram) was harder than prior quarter; management acknowledged but didn't preemptively disclose
How the street is positioned
Price & valuation: Stock at ₹2,209.5 (as of 2026-11-09) is down 54.07% from its all-time high of ₹4,810.8. It trades above its 20-day SMA (₹2,167.89) but well below its 50-day (₹2,393.42) and 200-day (₹2,694.15) averages—a downtrend confirmed. RSI at 46.5 shows no momentum overshoot either way; the stock is drifting. Volume trend is normal, not panic-selling, but the persistent drawdown is the market's own verdict: the growth story is not convincing at current capital intensity. Ownership flows: FII shareholding has contracted from 26.31% in Q1 FY26 to 22.34% in Q1 FY27—a drop of 3.97pp over five quarters. DIIs are flat (slightly down 0.73pp QoQ). Promoter stake stable at ~44%. The FII exit is the real signal: large institutions have de-risked TI, unconvinced by the TICMPL bet and the margin pressure. That vote of non-confidence matches the sell-off.
Consolidated revenue 32.7% YoY with core segments healthy; secular tailwinds in EV and medical intact
Free cash flow ₹167 Cr in Q2; FCF-to-PAT conversion at target 85%; debt/equity stable
Medical 20% growth and CDMO path to regulatory approval (next CY) are credible long-term bets
Net margin 5.7% reflects commodity surge and FX pressure, not operational miss; recovery lag is real
TICMPL volumes 20–30% below management's own comfort; external capital withdrew; breakeven unproven
Cost pass-through timeline 1–2 quarters hinges on market readiness; management said 'market may not be ready'
FII ownership down 3.97pp in five quarters; stock down 54% from ATH despite 39% PAT growth
TICMPL execution & profitability gap
HighFour EV businesses underperforming; analyst directly stated 'volumes should be higher.' Breakeven Q4 FY27 depends on unproven price increases and cost absorption. If profitability slips into Q1 FY28, capital is trapped and ROI credibility collapses.
Commodity and FX headwinds; cost pass-through lag
HighQ2 margin compression is real; recovery timeline 1–2 quarters is management's hope, not confirmed. If commodity prices persist or rupee stays weak, margin recovery is delayed further, eating into FY27 and FY28 earnings.
External capital withdrawal from TICMPL
HighPE partner has not invested further after initial ₹2,250 Cr stake. TI now fully funding Rs 600–700 Cr annual group capex on its own cash. If TICMPL struggles, TI absorbs 100% of capex drag with no partner to share upside.
Credibility strained; analysts pressing hard
MediumQ&A was unusually adversarial (Shah, Desai, Gnanasundaram pushing on volumes, costs, capital allocation). If next quarter repeats miss, analyst sentiment will shift from cautious to bearish, triggering further selling.
Customer concentration & pricing power
MediumMining is 40% of TICMPL truck revenue; fixed-route operators concentrated in Bengaluru, Delhi, Ahmedabad. If mining demand cools or EV adoption stalls in concentrated use cases, volumes will be under-estimated, not just under-managed.
Medical and CDMO profitability deferred
MediumAmortization drag ₹4 Cr/quarter; medical sustainable margins still unproven ('higher double-digit teen' post-Q3); CDMO approval ~1 year out. Near-term NPM will remain pressured until these scale.
1 · Cost pass-through evidence—pricing power
Did Q3 see meaningful price increases to OEMs and customers? Or did the 'market not ready' comment prove prescient? Margin trajectory is the bellwether.
2 · TICMPL volume acceleration
Q3 must show volumes materially higher than Q2—not just QoQ but a signal that the business can scale. Analyst bar is high after Q2 feedback. Truck and 3W units are the metrics to watch.
3 · TICMPL HCV breakeven Q4 timeline credibility
Q3 will show cost trajectory and customer adoption. If costs are still 50%+ above baseline or volume growth stalls, Q4 breakeven promise loses credibility and the stock re-rates lower.
4 · FII re-entry or continued exit
Watch Q3-Q4 F&O FII flows and bulk-block trades. If FII stays exiting, it signals street skepticism persists despite fundamental recovery.
TI's Q2 is a tale of two companies: the core engineering and metal business is executing well, growing 32%+ with stable returns. TICMPL and the margin pressure are the fracture lines. Growth without margin recovery at a company with high capex intensity is not a turnaround story; it's a capital trap in slow motion. The street has priced that skepticism in—stock down 54% from highs, FII exiting, analysts rating it Hold.
The quarter does not change the debate. Strong headline growth masks execution risk, and near-term margin recovery is uncertain. TI is not a sell, but it's a hold until TICMPL volumes and profitability credibly move higher and commodities stabilize. The number to track: Q3 TICMPL volumes and gross margins. That is the make-or-break metric for the next 12 months.
Informational and educational content only. Not investment advice.